196 related articles for article (PubMed ID: 22986144)
21. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).
Penson RT; Huang HQ; Wenzel LB; Monk BJ; Stockman S; Long HJ; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Method M; Michael H; Tewari KS
Lancet Oncol; 2015 Mar; 16(3):301-11. PubMed ID: 25638326
[TBL] [Abstract][Full Text] [Related]
22. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.
Untch M; Jackisch C; Schneeweiss A; Conrad B; Aktas B; Denkert C; Eidtmann H; Wiebringhaus H; Kümmel S; Hilfrich J; Warm M; Paepke S; Just M; Hanusch C; Hackmann J; Blohmer JU; Clemens M; Darb-Esfahani S; Schmitt WD; Dan Costa S; Gerber B; Engels K; Nekljudova V; Loibl S; von Minckwitz G; ;
Lancet Oncol; 2016 Mar; 17(3):345-356. PubMed ID: 26869049
[TBL] [Abstract][Full Text] [Related]
23. Phase 2 trial of paclitaxel, 13-cis retinoic acid, and interferon alfa-2b in the treatment of advanced stage or recurrent cervical cancer.
Song M; DiPaola RS; Cracchiolo BM; Gibbon DG; Hellmann M; Nieves-Neira W; Vaidya A; Wagreich AR; Shih WJ; Rodriguez-Rodriguez L
Int J Gynecol Cancer; 2014 Nov; 24(9):1636-41. PubMed ID: 25304678
[TBL] [Abstract][Full Text] [Related]
24. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Rose PG; Blessing JA; Gershenson DM; McGehee R
J Clin Oncol; 1999 Sep; 17(9):2676-80. PubMed ID: 10561341
[TBL] [Abstract][Full Text] [Related]
25. nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer.
Megerdichian C; Olimpiadi Y; Hurvitz SA
Cancer Treat Rev; 2014 Jun; 40(5):614-25. PubMed ID: 24560997
[TBL] [Abstract][Full Text] [Related]
26. Phase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: a Kansai Clinical Oncology Group study.
Takekuma M; Hirashima Y; Ito K; Tsubamoto H; Tabata T; Arakawa A; Itani Y; Furukawa N; Murakoshi H; Takeuchi S
Gynecol Oncol; 2012 Sep; 126(3):341-5. PubMed ID: 22609108
[TBL] [Abstract][Full Text] [Related]
27. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma.
Hersh EM; O'Day SJ; Ribas A; Samlowski WE; Gordon MS; Shechter DE; Clawson AA; Gonzalez R
Cancer; 2010 Jan; 116(1):155-63. PubMed ID: 19877111
[TBL] [Abstract][Full Text] [Related]
28. Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients.
Fabi A; Giannarelli D; Malaguti P; Ferretti G; Vari S; Papaldo P; Nisticò C; Caterino M; De Vita R; Mottolese M; Iacorossi L; Cognetti F
Drug Des Devel Ther; 2015; 9():6177-83. PubMed ID: 26640370
[TBL] [Abstract][Full Text] [Related]
29. Safety and Efficacy of Low-dose Nanoparticle Albumin-bound Paclitaxel for HER2-negative Metastatic Breast Cancer.
Takashima T; Kawajiri H; Nishimori T; Tei S; Nishimura S; Yamagata S; Tokunaga S; Mizuyama Y; Sunami T; Tezuka K; Ikeda K; Ogawa Y; Kashiwagi S; Noda S; Onoda N; Ishikawa T; Kudoh S; Takada M; Hirakawa K; Ohira M
Anticancer Res; 2018 Jan; 38(1):379-383. PubMed ID: 29277798
[TBL] [Abstract][Full Text] [Related]
30. A phase I/II study of extended field radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in patients with cervical carcinoma metastatic to the para-aortic lymph nodes: a Gynecologic Oncology Group study.
Walker JL; Morrison A; DiSilvestro P; von Gruenigen VE;
Gynecol Oncol; 2009 Jan; 112(1):78-84. PubMed ID: 19010522
[TBL] [Abstract][Full Text] [Related]
31. Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy.
Weiss JM; Pennell N; Deal AM; Morgensztern D; Bradford DS; Crane J; West HJ; Lee C; Pecot C; Stevenson JP; Irvin W; Socinski M; Stinchcombe T; Villaruz LC; Muss HB
Cancer; 2020 Mar; 126(5):1060-1067. PubMed ID: 31943168
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer.
Gong W; Sun P; Mu Z; Liu J; Yu C; Liu A
Anticancer Res; 2017 Aug; 37(8):4687-4691. PubMed ID: 28739772
[TBL] [Abstract][Full Text] [Related]
33. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
[TBL] [Abstract][Full Text] [Related]
34. A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852).
Thaker PH; Salani R; Brady WE; Lankes HA; Cohn DE; Mutch DG; Mannel RS; Bell-McGuinn KM; Di Silvestro PA; Jelovac D; Carter JS; Duan W; Resnick KE; Dizon DS; Aghajanian C; Fracasso PM
Ann Oncol; 2017 Mar; 28(3):505-511. PubMed ID: 27998970
[TBL] [Abstract][Full Text] [Related]
35. A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer.
Hosein PJ; de Lima Lopes G; Pastorini VH; Gomez C; Macintyre J; Zayas G; Reis I; Montero AJ; Merchan JR; Rocha Lima CM
Am J Clin Oncol; 2013 Apr; 36(2):151-6. PubMed ID: 22307213
[TBL] [Abstract][Full Text] [Related]
36. Activity of paclitaxel in advanced or recurrent squamous cell cancer of the cervix.
Kudelka AP; Winn R; Edwards CL; Downey G; Greenberg H; Dakhil SR; Freedman RS; Loyer E; Rusinkiewicz J; Gacrama P; Fueger R; Kavanagh JJ
Clin Cancer Res; 1996 Aug; 2(8):1285-8. PubMed ID: 9816298
[TBL] [Abstract][Full Text] [Related]
37. The role of paclitaxel in the management of patients with carcinoma of the cervix.
Thigpen T; Vance R; Khansur T; Malamud F
Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-41-S2-46. PubMed ID: 9045336
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group.
Lorusso D; Ferrandina G; Pignata S; Ludovisi M; Viganò R; Scalone S; Scollo P; Breda E; Pietragalla A; Scambia G
Ann Oncol; 2010 Jan; 21(1):61-6. PubMed ID: 19605508
[TBL] [Abstract][Full Text] [Related]
39. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).
Tewari KS; Sill MW; Penson RT; Huang H; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Michael HE; DiSaia PJ; Copeland LJ; Creasman WT; Stehman FB; Brady MF; Burger RA; Thigpen JT; Birrer MJ; Waggoner SE; Moore DH; Look KY; Koh WJ; Monk BJ
Lancet; 2017 Oct; 390(10103):1654-1663. PubMed ID: 28756902
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix.
Fiorica J; Holloway R; Ndubisi B; Orr J; Grendys E; Boothby R; DeCesare S; LaPolla J; Hoffman M; Patel J
Gynecol Oncol; 2002 Apr; 85(1):89-94. PubMed ID: 11925125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
